^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    JAK1 inhibitor

    Related drugs:
    2d
    UVIPWP: Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis (clinicaltrials.gov)
    P=N/A, N=70, Completed, Peking University First Hospital
    New trial
    |
    IL17A (Interleukin 17A)
    2d
    Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2025 --> Apr 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    paclitaxel • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide
    3d
    Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy (clinicaltrials.gov)
    P2, N=82, Completed, Innovaderm Research Inc. | Active, not recruiting --> Completed | Trial primary completion date: Nov 2025 --> Jun 2025
    Trial completion • Trial primary completion date
    4d
    PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Epidaza (chidamide) • golidocitinib (DZD4205)
    4d
    A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation (clinicaltrials.gov)
    P1/2, N=32, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    |
    AiSuDa (ivarmacitinib)
    5d
    SELECT-SLE: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (clinicaltrials.gov)
    P3, N=1000, Recruiting, AbbVie | Trial primary completion date: Dec 2026 --> Mar 2027
    Trial primary completion date • Adverse events
    5d
    A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA) (clinicaltrials.gov)
    P4, N=15, Active, not recruiting, University of Alabama at Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed
    5d
    NCI-2020-01626: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=79, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=60 --> 79 | Trial completion date: Dec 2029 --> Apr 2030
    Enrollment closed • Enrollment change • Trial completion date
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan
    6d
    A clinical study of ruxolitinib combined with reduced-dose HLH-1994 regimen in the treatment of adult hemophagocytic lymphohistiocytosis (ChiCTR2500115370)
    P=N/A, N=20, Not yet recruiting, Shandong Provincial Qianfoshan Hospital; Shandong Provincial Qianfoshan Hospital
    New trial
    |
    Jakafi (ruxolitinib)
    6d
    A real-world study on the influencing factors of the efficacy of ruxolitinib cream in the treatment of vitiligo (ChiCTR2500115141)
    P=N/A, N=170, Not yet recruiting, Peking University Third Hospital; Peking University Third Hospital
    New trial
    6d
    Effect analysis and mechanism study of Abrocitinib in the treatment of bullous pemphigoid (ChiCTR2500114958)
    P=N/A, N=30, Completed, Peking University First Hospital; Peking University First Hospital
    New trial
    |
    minocycline
    6d
    A randomized, open-label, single-dose, two-formulation, two-sequence, two-period, two-way crossover bioequivalence study to evaluate the bioequivalence of a single oral dose of the test formulation of upadacitinib extended-release tablets and the reference formulation of upadacitinib extended-release tablets (trade name: RINVOQ®/Rifu®) under postprandial conditions in healthy Chinese subjects. (ChiCTR2500114078)
    P=N/A, N=36, Not yet recruiting, Shulan (Hangzhou) Hospital; Shulan (Hangzhou) Hospital
    New trial